Jill Johnsen
Hematology & Oncology · Seattle, WANPI 1861578718
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $747,388 of the $991,129 with a category attached, or 75.4%. Octapharma USA, Inc. accounts for 78.6% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $726,355, 6.7 times the $108,036 reported in 2019. Among hematology & oncology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $12,872 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Octapharma USA, Inc.$779K
- Genentech, Inc.$194K
- Otsuka Pharmaceutical Co., Ltd.$9K
- CSL Behring$5K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Sanofi$191
- plus $197 from 2 others
Across 14 payments — averaging $173,600 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Octapharma USA, Inc.$2.4M
What the payments were for
- Consulting fees$8,5501%
- Speaking & faculty fees$747,38875%
- Grants$194,40020%
- Travel & lodging$39,6424%
- Food & beverage$1,1490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Octapharma USA, Inc. | 67 | $779,053 |
| Genentech, Inc. | 2 | $194,400 |
| Otsuka Pharmaceutical Co., Ltd. | 1 | $8,550 |
| CSL Behring | 1 | $5,363 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,375 |
| Sanofi | 2 | $191 |
| Genentech USA, Inc. | 2 | $172 |
| Novo Nordisk | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$991,129 in reported general payments places this provider in the 95th percentile of 349 hematology & oncology providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tranexamic Acid | 11 | $1,014 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
- Rebecca Kruse-JarresSeattle$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.